Trial Profile
Phase II trial to assess the combination of lenalidomide in patients with relapsed or refractory Hodgkin's lymphoma [ENSAYO FASE II PARA VALORAR LA COMBINACIÓN DE LENALIDOMIDA CON DOSIS METRONÓMICAS DE CICLOFOSFAMIDA EN PACIENTES CON LINFOMA DE HODGKIN CLÁSICO REFRACTARIO O EN RECAIDA]
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2016
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Lenalidomide (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 21 Jun 2011 New trial record